Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function

Journal of the National Cancer Institute

Volumn 88, Issue 12, 1996, Pages 817-824

  O'Reilly, Seamus ^a   Rowinsky, Eric ^a   Slichenmyer, William ^a   Donehower, Ross C ^a   Forastiere, Arlene ^a   Ettinger, David ^a   Chen, Tian Ling ^a   Sartorius, Susan ^a   Bowling, Katherine ^a   Smith, Jane ^b   Brubaker, Abe ^b   Lubejko, Barbara ^a   Ignacio, Virna ^a   Grochow, Louise B ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b BIOANALYTICAL SYSTEMS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG METABOLISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; LEUKEMIA; LIVER FUNCTION; PHASE 1 CLINICAL TRIAL; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LINEAR MODELS; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; TOPOTECAN;

EID: 15844424667     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.12.817     Document Type: Article

References (32)

1. Rowinsky EK, Grochow LB. Hendricks CB. Ettinger DS, Forasliere AA, Hurowitz LA, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase 1 inhibitor. J Clin Oncol 1992;10:647-56.
2. Haas NB, LaCreta FP, Walczak J, Hudes GR, Brennan JM, Ozols RF. et al. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res 1994; 54:1220-6.
3. Saltz L. Sirott M. Young C. Tong W, Niedzwiecki D, Tzy-Jyun Y, et al. Phase I clinical and pharmacologic study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factors [published erratum appears in J Natl Cancer Inst 1993; 85:1777]. J Natl Cancer Inst 1993;85:1499-507.
4. van Warmerdam LJ, Verweij J, Schellens JH, Rosing H, Davies BE, de Boer-Dennert M, et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 1995;35:237-45.
5. Rowinsky EK, Adjei A, Donehower RC, Gore SD, Jones RJ, Burke PJ, et al. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 1994;12:2193-203.
6. Grochow LB, Rowinsky EK, Johnson R. Ludeman S, Kaufmann SH, McCabe FL, et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 1992;20:706-13.
7. Topotecan Investigators Brochure. Smith-Kline Beecham Pharmaceuticals, King of Prussia, PA, 1994.
8. Kuhn J, Burris S. Irvin R, Wall R, Rodriguez G, Weiss G, et al. Pharmacokinetics of topotecan following a 30 minute or 3 day continuous infusion. Ann Oncol 1992;3:83. Suppl 1. Abstract.
9. Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB. Clinical pharmaco-dynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxocity. J Clin Oncol 1994;12:1946-54.
10. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda (MD): Division of Cancer Treatment, National Cancer Institute. 1988.
11. Jelliffe RW. Creatinine clearance: bedside estimate [letter]. Ann Intern Med 1973;79:604-5.
12. Crom WR, Webster SL, Bobo L, Teresi ME, Relling MV, Evans WE. Simultaneous administration of multiple model substrates to assess hepatic drug clearance. Clin Pharmacol Ther 1987;41:645-50.
13. Crom WR, Relling MV, Christensen ML. Rivera GK, Evans WE. Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. Clin Pharmacol Ther 1991;50:132-40.
14. Metzler CM, Elfring GC, McEwen AJ. A package of computer programs for pharmacokinetic modelling [letter]. Biometrics 1974; 30:3.
15. Box GE, Lucas HL. Design of experiments in nonlinear situations. Biometrika 1959;46:77-90.
16. Riley CA. Evans WE. Simultaneous analysis of antipyrine and lorazepam by high-performance liquid chromatography. J Chromatogr 1986;382:199-205.
17. Metzler CM. Extended least squares (ELS) for pharmacokinetic models. J Pharm Sci 1987; 76:565-71.
18. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-75.
19. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978;6: 539-46.
20. Charter MK. The estimate of moments: a technical note. J Pharmacokinet Biopharm 1989; 17:203-8.
21. Rowland M, Tozer TN. Clinical pharmaco-kinetics: concepts and applications. 3rd ed. Media (PA): Williams & Wilkins, 1995:340-66.
22. Altman DG. Practical statistics for medical research. 1st ed. London: Chapman & Hall, 1991.
23. Brockmoller J, Roots I. Assessment of liver metabolic function. Clinical implications. Clin Pharmacokinet 1994;27:216-48.
24. Gonzalez FJ. Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 1992;13:346-52.
25. Tephly TR, Burchell B. UDP-glucuronyl-transferases: a family of detoxifying enzymes. Trends Pharmacol Sci 1990;11:276-9.
26. Caeser J, Shaldon S, Chiandussi L, Guevara L, Sherlock S. The use of indocyanine green in the management of hepatic blood flow and as a test of hepatic function. Clin Sci 1961;21:43-57.
27. Skak C, Keiding S. Methodological problems in the use of indocyanine green to estimate hepatic blood flow and ICG clearance in man. Liver 1987;7:155-62.
28. Burke TG, Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 1994;37:40-6.
29. Mi Z, Malak H, Burke TG. Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry 1995;34:13722-8.
30. Roy D. Munshi CB, Mi Z, Burke TG. Alteration of uptake and cytotoxicity of camptothecin drugs in MCF-7 breast cancer cells by human serum albumin. Proc Am Assoc Cancer Res 1995;36:444.
31. Arbuck SG, Douglass HO, Crom WR, Goodwin P, Silk Y, Cooper C, et al. Etoposide pharmacokinetics in patients with normal and abnormal organ function. J Clin Oncol 1986; 4:1690-5.
32. Hande KR, Wolff SN, Greco FA, Hainsworth JD, Reed G, Johnson DH. Etoposide kinetics in patients with obstructive jaundice [see comment citation in Medline], J Clin Oncol 1990; 8:1101-7.